Short description
Equillium is a biotechnology company that develops products for autoimmune and inflammatory disorders with an unmet medical need.
Description
Equillium Inc is a biotechnology company that develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with an unmet medical need. Its primary product candidate is EQ001, which is a clinical-stage first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in effector T cell activity, which drives a number of immuno-inflammatory diseases such as graft versus host disease, asthma, uveitis, colitis, lupus, and multiple sclerosis.
Last funding
Noaccess
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
La Jolla, California, United States, North America
Founded on
January 1, 2017
Exited on
October 12, 2018
Went public on
October 12, 2018
Stock symbol
EQ
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$7890 - 12340
Sign in for full access
Investors
No Way, Noaccess, Uh Ohhhh, No Way, Absolutely Noaccess, Nopepepe
Sign in for full access
Founders
Bruce D. Steel, Stephen Connelly